Mai Lin1, Michael J Welch, Suzanne E Lapi. 1. Mallinckrodt Institute of Radiology, Washington University School of Medicine, Campus Box.8225, 510 South Kingshighway Blvd, St. Louis, MO, 63110, USA.
Abstract
PURPOSE: Somatostatin receptors (SSTR) have been reported as promising targets for imaging agents for cancer. Recently, (68)Ga-DOTATOC-based PET imaging has been used successfully for diagnosis and management of SSTR-expressing tumors. The purpose of this study was to evaluate the influence of chelator modifications and charge on (68)Ga-labeled peptide conjugates. PROCEDURES: We have synthesized a series of [Tyr(3)]octreotide conjugates that consisted of different NOTA-based chelators with two to five carboxylate moieties, and compared our results with (68)Ga-DOTATOC in both in vitro and in vivo studies. RESULTS: With the exception of (68)Ga-1 (three carboxylates), the increased number of carboxylates on the NOTA-based chelators resulted in a reduced binding affinity and internalization. Additionally, the tumor uptake for (68)Ga-2 (four carboxylates) and (68)Ga-3 (five carboxylates) was reduced compared to that of (68)Ga-DOTATOC (three carboxylates) and (68)Ga-NO2ATOC (two carboxylates) and (68)Ga-1 (three carboxylates) at 2 h p.i. suggesting the presence of an optimal charge for this compound. CONCLUSIONS: Chelator modifications can lead to the altered pharmacokinetics. These results may impact further design considerations for peptide-based imaging agents.
PURPOSE:Somatostatin receptors (SSTR) have been reported as promising targets for imaging agents for cancer. Recently, (68)Ga-DOTATOC-based PET imaging has been used successfully for diagnosis and management of SSTR-expressing tumors. The purpose of this study was to evaluate the influence of chelator modifications and charge on (68)Ga-labeled peptide conjugates. PROCEDURES: We have synthesized a series of [Tyr(3)]octreotide conjugates that consisted of different NOTA-based chelators with two to five carboxylate moieties, and compared our results with (68)Ga-DOTATOC in both in vitro and in vivo studies. RESULTS: With the exception of (68)Ga-1 (three carboxylates), the increased number of carboxylates on the NOTA-based chelators resulted in a reduced binding affinity and internalization. Additionally, the tumor uptake for (68)Ga-2 (four carboxylates) and (68)Ga-3 (five carboxylates) was reduced compared to that of (68)Ga-DOTATOC (three carboxylates) and (68)Ga-NO2ATOC (two carboxylates) and (68)Ga-1 (three carboxylates) at 2 h p.i. suggesting the presence of an optimal charge for this compound. CONCLUSIONS: Chelator modifications can lead to the altered pharmacokinetics. These results may impact further design considerations for peptide-based imaging agents.
Authors: Klaus-Peter Eisenwiener; M I M Prata; I Buschmann; Han-Wen Zhang; A C Santos; Sandra Wenger; Jean Claude Reubi; Helmut R Mäcke Journal: Bioconjug Chem Date: 2002 May-Jun Impact factor: 4.774
Authors: D J Kwekkeboom; W H Bakker; P P Kooij; M W Konijnenberg; A Srinivasan; J L Erion; M A Schmidt; J L Bugaj; M de Jong; E P Krenning Journal: Eur J Nucl Med Date: 2001-09
Authors: Suzanne M Verwijnen; Peter A E Sillevis Smith; Rob C Hoeben; Martin J W E Rabelink; Leonard Wiebe; David T Curiel; Akseli Hemminki; Eric P Krenning; Marion de Jong Journal: Cancer Biother Radiopharm Date: 2004-02 Impact factor: 3.099
Authors: Erik Vegt; Annemarie Eek; Wim J G Oyen; Marion de Jong; Martin Gotthardt; Otto C Boerman Journal: Eur J Nucl Med Mol Imaging Date: 2009-09-01 Impact factor: 9.236
Authors: Jessie R Nedrow; Alexander G White; Jalpa Modi; Kim Nguyen; Albert J Chang; Carolyn J Anderson Journal: Mol Imaging Date: 2014 Impact factor: 4.488
Authors: Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis Journal: Inorg Chem Date: 2013-12-06 Impact factor: 5.165
Authors: Nilantha Bandara; Alex Zheleznyak; Kaavya Cherukuri; David A Griffith; Chris Limberakis; David A Tess; Chen Jianqing; Rikki Waterhouse; Suzanne E Lapi Journal: Mol Imaging Biol Date: 2016-02 Impact factor: 3.488